Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics (MCRB)
NASDAQ:MCRB
Earnings Data
Report Date
Nov 18, 2025Before Open (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
0.42Last Year’s EPS
11.6Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical developments, particularly with SER-155, and effective financial management. However, challenges remain in funding and the broader biotech environment, creating a balanced view between achievements and hurdles.Company Guidance -
Q3 2025
Promising Results for SER-155
SER-155 Phase Ib study showed a 77% relative risk reduction in bloodstream infections compared to placebo in patients undergoing allo-HSCT, with a number needed to treat of 3 for preventing one infection. The study also confirmed the safety profile of SER-155, similar to placebo.
Phase II Study Plans for SER-155
The proposed Phase II study for SER-155 is designed to be a well-powered, placebo-controlled study targeting approximately 248 participants with the primary endpoint of preventing bloodstream infections. Interim data is expected within 12 months of study initiation.
Robust Financial Management
Net loss from continuing operations decreased to $19.9 million in Q2 2025 from $26.2 million in Q2 2024. Research and development expenses also decreased by $2.9 million compared to the previous year.
Partnership and Funding Initiatives
Active discussions with multiple parties for potential partnerships, out-licensing deals, and mergers. Received a $25 million installment payment from Nestlé.
Positive Developments in Europe
Feedback from European KOLs was positive regarding the potential of SER-155, and plans are in place to include European countries in the Phase II study.
MCRB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MCRB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 06, 2025 | $14.28 | $13.78 | -3.50% |
May 07, 2025 | $8.55 | $8.29 | -3.04% |
Mar 13, 2025 | $13.86 | $12.77 | -7.86% |
Nov 13, 2024 | $13.28 | $11.80 | -11.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Seres Therapeutics (MCRB) report earnings?
Seres Therapeutics (MCRB) is schdueled to report earning on Nov 18, 2025, Before Open (Confirmed).
What is Seres Therapeutics (MCRB) earnings time?
Seres Therapeutics (MCRB) earnings time is at Nov 18, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MCRB EPS forecast?
MCRB EPS forecast for the fiscal quarter 2025 (Q3) is 0.42.